The New England journal of medicine · 2023 · Clinical trial · PMID 37366315
Explore the library
Limited human evidenceInvestigational triple-receptor agonist
Retatrutide
Retatrutide is an investigational peptide designed to target three metabolic hormone receptors. Published human research does not itself establish regulatory approval.
Also indexed as: LY3437943
A clear starting point
Retatrutide is an investigational peptide designed to target three metabolic hormone receptors. Published human research does not itself establish regulatory approval.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
GLP-1 / GIP / glucagon
Retatrutide is an investigational peptide designed to target three metabolic hormone receptors. Published human research does not itself establish regulatory approval.
- Targets & processes
- GLP-1 / GIP / glucagon
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
Body-weight and metabolic outcomes in controlled trials.
What this does not establish
The cited phase 2 trial supports further investigation; a published trial is not FDA approval.
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
Gastrointestinal adverse effects and increased heart rate have been reported in trials. Long-term benefit–risk and use outside trial protocols remain uncertain.
Contraindications & cautions
Not an exhaustive contraindication review. Gastrointestinal adverse effects and increased heart rate have been reported in trials. Long-term benefit–risk and use outside trial protocols remain uncertain.
Medication & supplement interactions
Interaction information is incomplete. Gastrointestinal adverse effects and increased heart rate have been reported in trials. Long-term benefit–risk and use outside trial protocols remain uncertain.
Regulatory status · United States
Not FDA-approved. No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
This is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.